CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 12, 2024, to holders of record as of June 28, 2024. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innov ...

Have you evaluated the performance of Dentsply International's (XRAY) international operations for the quarter ending March 2024? Given the extensive global presence of this dental products manufacturer, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. I ...

财务数据和关键指标变化 - 第一季度收入为9.53亿美元,同比下降2.6% [9] - 第一季度调整后每股收益为0.42美元,同比增长近8% [6] - 公司维持全年有机销售和调整后每股收益的指引范围,但预计将趋向于下限 [6] - 公司调整净销售额,增加了额外的汇率不利影响 [6] 各条业务线数据和关键指标变化 - 连接技术解决方案(CTS)业务有机销售下降5.7%,主要由于影像设备销售大幅下降 [11][12] - 正畸和种植解决方案业务有机销售增长5.6%,其中牙列矫正业务增长14% [11] - 基本牙科解决方案业务有机销售下降5.5%,受到去年同期强劲反弹的影响 [11] - Wellspect HealthCare业务有机销售增长约5% [12] 各个市场数据和关键指标变化 - 美国有机销售增长1.4%,受益于牙列矫正和CAD/CAM的强劲增长 [13] - 欧洲有机销售下降5.8%,主要受基本牙科解决方案和设备销售下降的影响 [13] - 德国市场下降超过15%,公司预计第二季度仍将下降两位数 [47][48] 公司战略和发展方向及行业竞争 - 公司正在推进供应链转型和SKU优化等基础性举措,预计将在2024年下半年开始产生财务效益 [16] - 公司正在加快企业数字化转型,包括DS Core平台的推广、ERP现代化和数据与AI战略 [16][17] - 公司正在加大在正畸、种植和失禁护理等高增长领域的投资,如拓展Byte和SureSmile业务 [17] - 公司正在采取措施应对影像设备市场的挑战,如重新推出Orthophos SL产品线 [29][30] 管理层对经营环境和未来前景的评论 - 公司对2024年全年有机销售和调整后每股收益的指引趋于下限持谨慎态度,主要受到影像设备业务的宏观不确定性影响 [6] - 公司正采取收紧成本控制等措施,以更好地实现盈利能力和每股收益目标 [6][35] - 公司对长期发展前景保持信心,认为正在执行的战略举措将使公司在更正常的宏观环境下实现盈利增长 [18] 问答环节重要的提问和回答 问题1 **David Saxon 提问** 对于公司各业务线的增长预期,是否有更新?CTS业务是否会下降? [21][22] **Glenn Coleman 回答** 预计Essential Dental Solutions全年基本持平,Ortho业务将实现20%以上的增长,Implants业务将保持低个位数增长,CTS业务全年将下降中个位数 [22][23][24] 问题2 **Jeff Johnson 提问** 公司是否需要持续降低产品平均售价,以应对客户对成本的关注? [29][30][31][32] **Glenn Coleman 回答** 公司希望为客户提供不同价位的产品选择,既有高端产品也有价值产品,以满足不同客户需求 [31][32] 问题3 **Dylan Finley 提问** 公司是否会采取额外的成本控制措施,对2024年的利润产生影响? [34][35] **Glenn Coleman 回答** 如果公司面临更多的收入压力,会采取额外的成本控制措施,这些措施将在2024年产生影响 [35]

DENTSPLY SIRONA Inc. (XRAY) reported first-quarter 2024 adjusted earnings per share (EPS) of 42 cents, which aligns with the Zacks Consensus Estimate. The bottom line improved 7.9% on a year-over-year basis. On a GAAP basis, the company reported an EPS of 9 cents against the loss of 9 cents per share reported in the year-ago quarter. Revenues Revenues in the reported quarter totaled $953 million, which missed the Zacks Consensus Estimate by 1.8%. The top line declined 2.6% year over year and 1.9% on an orga ...

For the quarter ended March 2024, Dentsply International (XRAY) reported revenue of $953 million, down 2.6% over the same period last year. EPS came in at $0.42, compared to $0.39 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $969.84 million, representing a surprise of -1.74%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.42. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) Delaware 39-1434669 (State or other jurisdiction of (I.R.S. Em ...

Dentsply International (XRAY) came out with quarterly earnings of $0.42 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this dental products manufacturer would post earnings of $0.43 per share when it actually produced earnings of $0.44, delivering a surprise of 2.33%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. ...

Dentsply Sirona Reports First Quarter 2024 Results • Net sales of $953 million decreased (2.6%), organic sales decreased (1.9%) • GAAP gross margin of 53.1%, GAAP net income of $18 million or $0.09 per share • Adjusted EBITDA margin of 16.8%, adjusted EPS of $0.42 • Maintaining FY24 outlook for organic sales and adjusted EPS, trending towards the low-end of both ranges; reported sales adjusted for additional foreign currency impact • Company expects to repurchase up to $150 million of its common stock in Q2 ...

DENTSPLY SIRONA Inc. (XRAY) is scheduled to release first-quarter 2024 results on May 2, before the opening bell. In the last reported quarter, the company’s earnings beat estimates by 2.33%. It delivered an average earnings surprise of 10.3% in the past four quarters. Q1 Estimates The Zacks Consensus Estimate for revenues is pegged at $969.8 million. The consensus mark for earnings is pinned at 42 cents per share. Factors to Note DENTSPLY SIRONA’s Orthodontic and Implant Solutions segment witnessed revenue ...

CHARLOTTE, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 2, 2024, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be ava ...